Jardiance Off-Label Uses with Evidence Levels

Empagliflozin, sold under the brand name Jardiance, is a once-daily oral SGLT2 (sodium-glucose cotransporter 2) inhibitor. The FDA has approved empagliflozin for type 2 diabetes, heart failure regardless of ejection fraction, and slowing chronic kidney disease progression. Uses discussed below for fatty liver disease, gout, polycystic kidney disease, obesity, and select cardiac and renal conditions represent off-label applications, in which a doctor prescribes empagliflozin for conditions beyond those on the FDA label, guided by clinical reasoning and research evidence.

The direct answer

Off-label empagliflozin use is best supported, though still not definitive, for two conditions: reducing liver fat in people who already have type 2 diabetes and fatty liver disease, and lowering serum uric acid in people who already have a cardiometabolic reason to take the drug (diabetes, heart failure, or CKD). Evidence for polycystic kidney disease, standalone weight loss, post-acute-kidney-injury renoprotection, and subclinical diabetic cardiomyopathy is preliminary: mechanistically plausible, supported by small or observational studies, and not yet confirmed by an outcomes trial. No professional guideline currently recommends starting empagliflozin solely for any of these off-label reasons in a patient who has no other indication for the drug.

How the mechanism explains the off-label interest

Empagliflozin blocks SGLT2, the transporter responsible for most glucose reabsorption in the proximal renal tubule. Blocking it causes the kidneys to excrete glucose in the urine instead of reabsorbing it, which produces a modest daily caloric loss and contributes to weight reduction. That single mechanism sets off several downstream effects that have nothing to do with blood sugar: osmotic diuresis that lowers cardiac preload, restoration of tubuloglomerular feedback that lowers pressure inside the glomerulus, a mild rise in ketone body production that may serve as an alternate cardiac fuel source, and increased uric acid excretion through competition at the URAT1 transporter.

The EMPA-REG OUTCOME trial, which established empagliflozin's cardiovascular benefit in people with type 2 diabetes and existing cardiovascular disease, was the first large trial to show that an SGLT2 inhibitor could reduce cardiovascular death independent of glucose control. That finding is why researchers have since tested the drug in liver disease, gout, kidney cyst disorders, and heart failure phenotypes well outside its original diabetes indication. It does not mean each of those applications has been proven; it explains why they were worth studying.

Evidence at a glance

Should you ask about Jardiance for fatty liver disease (NAFLD/MASLD)?

Small randomized trials in people with type 2 diabetes and non-alcoholic fatty liver disease have shown that empagliflozin can meaningfully reduce liver fat, measured by MRI-based proton density fat fraction, over roughly 20 weeks compared with standard care. The proposed mechanism includes reduced hepatic fat synthesis, better insulin sensitivity, and the caloric deficit from glycosuria.

No trial has yet been powered to show that empagliflozin changes liver fibrosis stage or produces NASH resolution, which are the endpoints that matter most for long-term liver outcomes. Major liver societies have not added SGLT2 inhibitors to formal fatty liver treatment guidelines, though diabetes-focused guidance acknowledges the plausible co-benefit in patients who already have diabetes. This is a reasonable conversation to have with a treating physician if a patient already has type 2 diabetes and fatty liver disease, not a reason to start the drug in someone who has neither diabetes nor another approved indication.

Should you ask about Jardiance for gout or high uric acid?

SGLT2 inhibitors lower serum uric acid by competing with urate at the same renal transporters, and post-hoc analysis of empagliflozin's cardiovascular outcomes trial showed a measurable drop in uric acid alongside the drug's cardiovascular benefit. A large claims-based cohort study comparing new SGLT2 inhibitor users with users of a different diabetes drug class found a substantially lower rate of gout flares in the SGLT2 inhibitor group, though as with any non-randomized comparison, some of that difference could reflect differences between the patients who were prescribed each drug rather than the drug itself.

For a patient who already qualifies for empagliflozin because of diabetes, heart failure, or CKD, and who also has gout, this is a legitimate dual-purpose conversation. Starting empagliflozin in an otherwise healthy person purely to prevent gout is not supported by any completed randomized trial designed for that purpose.

Should you ask about Jardiance for polycystic kidney disease (ADPKD)?

The rationale here is mostly preclinical: cells affected by polycystin deficiency appear to depend heavily on glucose metabolism, and reducing glucose availability might slow cyst growth. A small phase 2 crossover trial in adults with ADPKD found empagliflozin was tolerated reasonably well and showed a non-significant trend toward slower kidney volume growth, not a confirmed benefit. A larger trial is underway and is not expected to report results for at least another year or two from this writing (2026).

This is the weakest tier of off-label evidence discussed on this page. Clinical advisory statements have not recommended routine SGLT2 inhibitor use in ADPKD outside of a clinical trial, and a patient considering this should understand that current data cannot yet answer whether the drug actually slows disease progression.

Should you ask about Jardiance as a weight-loss adjunct?

On its own, empagliflozin produces modest weight loss, generally in the low single-digit kilogram range over many months, driven by glycosuria and mild diuresis. That effect is smaller in people without diabetes, because there is less excess glucose to excrete, and it plateaus well below what GLP-1 receptor agonists or bariatric interventions achieve. No one should expect Jardiance alone to produce substantial body weight loss.

Where the drug has a more defensible adjunct role is alongside GLP-1 receptor agonist therapy (semaglutide, tirzepatide, and similar drugs), particularly in patients who develop peripheral edema or whose blood pressure remains elevated on GLP-1 therapy alone. Some obesity treatment algorithms list SGLT2 inhibitors as an option to consider in combination for patients with elevated BMI and cardiovascular risk factors, not as a standalone weight-loss drug.

Should you ask about Jardiance for diastolic dysfunction without a formal heart failure diagnosis?

Empagliflozin is FDA-approved for heart failure with preserved ejection fraction (HFpEF) based on a large outcomes trial that showed a meaningful reduction in cardiovascular death or heart failure hospitalization. That approval covers people who already meet HFpEF diagnostic criteria.

Some cardiologists extend the same reasoning to patients who show early echocardiographic signs of impaired relaxation but do not yet meet the formal criteria for an HFpEF diagnosis, on the argument that diastolic dysfunction and HFpEF likely represent points on the same disease continuum rather than separate conditions. That is a plausible clinical argument, not a tested one: no trial has specifically enrolled patients with isolated diastolic dysfunction and no heart failure diagnosis. Any benefit in that earlier population is extrapolated from the approved HFpEF population, which is a meaningfully different evidence standard.

Should you ask about Jardiance after an acute kidney injury?

People who survive an episode of acute kidney injury (AKI) face a substantially elevated long-term risk of progressing to advanced chronic kidney disease. Because SGLT2 inhibitors lower pressure inside the glomerulus and reduce albuminuria in other settings, researchers have asked whether starting the drug soon after an AKI episode could reduce that long-term risk.

An observational cohort study found that people who started an SGLT2 inhibitor within roughly three months of an AKI episode had a lower rate of major kidney events over the following two years compared with those who did not. Cohort comparisons like this carry a real risk of confounding by indication: patients healthy enough to be started on a new oral medication after AKI may have had a better underlying prognosis regardless of the drug. A large chronic kidney disease outcomes trial that included a post-AKI subgroup showed a consistent direction of benefit, but that subgroup was small. Prospective trials designed specifically to test post-AKI initiation are still in the planning stage as of this writing.

Should you ask about Jardiance for diabetic cardiomyopathy without heart failure?

People with long-standing type 2 diabetes can develop structural changes in the heart, thickening and fibrosis, well before ejection fraction falls or symptoms appear. This entity, sometimes called diabetic cardiomyopathy, has no FDA-approved treatment. A cardiac MRI substudy within empagliflozin's diabetes cardiovascular trial program found a reduction in left ventricular mass over about a year compared with placebo, appearing within a few months and persisting.

That is a structural finding, not an outcomes finding. No trial has shown that treating subclinical diabetic cardiomyopathy with empagliflozin prevents later progression to symptomatic heart failure. This remains the most speculative use on this page.

Safety considerations that matter more in off-label populations

Empagliflozin's safety profile is well characterized from its diabetes and heart failure trial programs. The risks that matter most when the drug is used off-label, often in people who do not have diabetes, include:

• Genital yeast infections, more common in women, generally in the range of several percent of users
• Euglycemic diabetic ketoacidosis, uncommon but reported in non-diabetic heart failure trial populations, and a risk that non-diabetic patients may not recognize because their blood glucose stays normal
• Volume depletion, particularly in older adults or anyone also taking a loop diuretic
• Fournier gangrene, a rare but serious genital infection that carries an FDA boxed warning for the drug class

Because euglycemic ketoacidosis does not present with high blood sugar, non-diabetic patients starting empagliflozin off-label need specific counseling: stop the drug during acute illness, before surgery, or during prolonged fasting, and seek urgent care for unexplained nausea, vomiting, abdominal pain, or unusual fatigue even if a home glucose check looks normal.

Empagliflozin's glucose-lowering effect weakens as kidney function declines below an eGFR of roughly 45 mL/min/1.73 m², but its cardiovascular and kidney-protective effects appear to persist at much lower eGFR levels based on chronic kidney disease trial data. A drop in eGFR alone is not automatically a reason to stop the drug if it is otherwise well tolerated; that decision belongs with the prescribing clinician.

Before starting empagliflozin off-label, reasonable baseline evaluation includes a metabolic panel, urinalysis, and HbA1c, partly to rule out undiagnosed diabetes, which would make the prescription an on-label one instead. The drug is not appropriate off-label for people with recurrent urinary tract infections, active foot ulcers, or type 1 diabetes, given the unfavorable risk-benefit balance in those groups.

A decision framework for evaluating an off-label Jardiance conversation

This information is designed to support discussion with your prescribing clinician and should not replace that conversation. It does not offer personalized dosing recommendations or diagnostic guidance.

Step 1: Do you already have an on-label reason to take empagliflozin? If yes (type 2 diabetes, heart failure, or CKD with reduced eGFR or albuminuria), any of the off-label benefits discussed above become a genuine secondary reason to prefer this drug over an alternative in the same class or category. If no, the bar for starting the drug purely for an off-label reason is much higher, and for ADPKD, isolated diastolic dysfunction, and post-AKI renoprotection, current evidence does not clearly clear that bar.

Step 2: Match the off-label reason to its evidence tier. Tier B uses (NAFLD/MASLD in diabetic patients, gout prevention in cardiometabolic patients, GLP-1 combination for weight and blood pressure, extrapolated diastolic dysfunction) are reasonable topics to raise proactively with a clinician. Tier C uses (ADPKD, post-AKI renoprotection, subclinical diabetic cardiomyopathy) are reasonable to ask about only in the context of a clinical trial or as a considered judgment call by a specialist who understands the data are incomplete.

Step 3: Check for a disqualifying condition. Type 1 diabetes, recurrent UTIs, active foot ulcers, a history of Fournier gangrene, or an inability to reliably hold the drug around illness/surgery should prompt a conversation about alternatives regardless of which off-label benefit is being sought.

Step 4: Set a monitoring and stopping plan before starting. Baseline metabolic panel, urinalysis, and HbA1c; a plan to pause the drug during acute illness, fasting, or before surgery; and a clear understanding that nausea, vomiting, or abdominal pain warrant urgent evaluation even with a normal glucose reading, since euglycemic ketoacidosis will not show up on a home glucose check.

Step 5: Revisit at a defined interval. For liver fat or uric acid goals, a follow-up measurement at 3 to 6 months is reasonable. For ADPKD or post-AKI use, the honest answer is that no established interval exists yet, because no trial has defined one; this should be treated as an open question rather than settled monitoring guidance.

What is established, what is plausible, and what is not established

Established: Empagliflozin is FDA-approved for type 2 diabetes, heart failure across the ejection fraction range, and reduction of CKD progression, based on large randomized outcomes trials. Its class-level safety risks (genital infections, euglycemic DKA, volume depletion, Fournier gangrene) are well documented.

Plausible but not proven: Meaningful reduction in liver fat in diabetic patients with fatty liver disease, uric acid lowering with associated reduction in gout flares in cardiometabolic patients, adjunctive weight and blood-pressure benefit alongside GLP-1 therapy, and benefit in early diastolic dysfunction that has not yet progressed to a formal HFpEF diagnosis. Each rests on smaller trials or observational data rather than a dedicated outcomes trial.

Not established: That empagliflozin slows cyst growth or delays kidney failure in ADPKD, that starting it after acute kidney injury prevents progression to chronic kidney disease, or that it prevents progression from subclinical diabetic cardiomyopathy to symptomatic heart failure. These uses rest on mechanistic reasoning and early-phase or observational data, and dedicated outcomes trials have not yet reported results.

Off-label prescribing decisions should be made with a treating clinician who can weigh a patient's full medical history, kidney function, and other medications. This article summarizes published research trends and does not substitute for individualized medical advice, diagnosis, or a specific dosing recommendation.